Provided by Tiger Trade Technology Pte. Ltd.

Klotho Neurosciences, Inc.

0.2402
+0.01958.84%
Post-market: 0.2300-0.0102-4.25%19:54 EST
Volume:605.21K
Turnover:141.13K
Market Cap:17.66M
PE:-0.79
High:0.2427
Open:0.2309
Low:0.2229
Close:0.2207
52wk High:3.91
52wk Low:0.1135
Shares:73.54M
Float Shares:56.78M
Volume Ratio:0.82
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3046
EPS(LYR):-0.3195
ROE:-198.28%
ROA:-71.63%
PB:1.78
PE(LYR):-0.75

Loading ...

Klotho Neuroscience Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Jan 13

Klotho Neuroscience Sells $15M in Series C Preferred Stock to Sigma9 Capital

Reuters
·
Dec 09, 2025

Klotho Neurosciences Inc - Files Prospectus for Offer and Resale by Selling Stockholders of up to 34.9 Mln Shares of Common Stock

THOMSON REUTERS
·
Dec 06, 2025

Klotho Neurosciences Q3 EPS $(0.05) Up From $(0.18) YoY

Benzinga
·
Nov 14, 2025

Klotho and Turn allow Letter of Intent to expire

TIPRANKS
·
Oct 08, 2025

BRIEF-Klotho Neurosciences Announces Expiration Of Letter Of Intent

Reuters
·
Oct 08, 2025

Klotho Neurosciences Inc: Loi With Turn Biotechnologies Allowed to Expire by Parties

THOMSON REUTERS
·
Oct 08, 2025

Klotho Neurosciences Announces Expiration of Letter of Intent

THOMSON REUTERS
·
Oct 08, 2025

Klotho Neurosciences Inc - to Buy $300 Mln Signed Out-Licensing and Co-Development Partnership With South Korean Pharma Cos

THOMSON REUTERS
·
Sep 30, 2025

Klotho Neurosciences Inc - Plans to Rebrand After Deal Completion

THOMSON REUTERS
·
Sep 30, 2025

Klotho Neurosciences Inc - to Buy Turn's Era Platform and Eturna Rna Delivery System

THOMSON REUTERS
·
Sep 30, 2025

Press Release: Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership

Dow Jones
·
Sep 30, 2025

Klotho Neuroscience Extends Private Placement Agreement, Caps Share Offering at 6.76 Million

Reuters
·
Sep 26, 2025

Klotho Neuroscience Inc. Receives Nasdaq Delisting Warning for Failure to Maintain $1 Minimum Bid Price

Reuters
·
Sep 26, 2025

Klotho Neurosciences CEO to Attend Inaugural Klotho Conference & Scientific Seminar in Irvine, California

Reuters
·
Sep 08, 2025

Klotho Neurosciences Q2 EPS $(0.12) Down From $(0.03) YoY

Benzinga
·
Aug 18, 2025

Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development

Reuters
·
Aug 18, 2025

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

THOMSON REUTERS
·
Aug 18, 2025

Klotho Neuroscience Inc. Delays Q2 2025 Financial Report Due to Incomplete Financial Statements

Reuters
·
Aug 14, 2025

Klotho Neuroscience Unveils Breakthrough in Gene Therapy Manufacturing with AAVnerGene Collaboration

Reuters
·
Aug 12, 2025